The Fort Worth Press - Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

USD -
AED 3.672498
AFN 63.999702
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.498647
ARS 1549.870021
AUD 1.484032
AWG 1.8025
AZN 1.696134
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.7845
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.43019
CDF 2317.999943
CHF 0.838915
CLF 0.025357
CLP 997.979904
CNY 6.66455
CNH 6.66546
COP 3317.23
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.17145
DJF 178.348063
DKK 6.78993
DOP 60.867113
DZD 137.008028
EGP 53.678304
ERN 15
ETB 164.376481
EUR 0.90833
FJD 2.296799
FKP 0.758367
GBP 0.757835
GEL 2.594988
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.501169
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846035
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 330.815503
IDR 18233.75
ILS 3.248749
IMP 0.758367
INR 93.57705
IQD 1518.259596
IRR 1925253.9999
ISK 124.25976
JEP 0.758367
JMD 158.794125
JOD 0.708947
JPY 159.196501
KES 130.050152
KGS 87.449398
KHR 4106.5296
KMF 447.498309
KPW 900.00035
KRW 1338.809943
KWD 0.311439
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.91772
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859839
MVR 15.410333
MWK 1736.583325
MXN 18.50519
MYR 4.091198
MZN 63.909632
NAD 16.970667
NGN 1346.080103
NIO 36.851561
NOK 9.64695
NPR 150.403886
NZD 1.81999
OMR 0.384499
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.736022
PKR 276.920096
PLN 3.99624
PYG 6215.118421
QAR 3.660925
RON 4.854006
RSD 106.818972
RUB 82.598925
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 14.276828
SDG 601.518606
SEK 10.083204
SGD 1.288005
SHP 0.758581
SLE 23.049833
SLL 20969.503664
SOS 572.372042
SRD 37.4535
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.82499
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417195
TTD 6.801694
TWD 32.962498
TZS 2651.997978
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603596
VND 25735
VUV 120.845902
WST 2.802705
XAF 595.82556
XAG 0.021012
XAU 0.0002579996
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 595.82556
XPF 108.488699
YER 236.49594
ZAR 16.959115
ZMK 9001.1985
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.075993
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

- Signals Start of New Commercialization Phase for LineaRx Subsidiary -

- Company Negotiating GMP Supply Agreement -

- Company Reaffirms Strategic Restructuring Timeline -

Text size:

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month. The Company also announced that it is actively negotiating a supply agreement for GMP IVT template with a mRNA therapeutic developer.

Separately, the Company reaffirmed its intention to complete the implementation of its previously announced strategic restructuring plan by the end of the current quarter. The restructuring is intended to drive sustainable growth from LineaRx, Inc., its biotherapeutic subsidiary, optimize Applied DNA's cost structure, and extend the parent company's cash runway.

GMP Facility Overview:

  • Based on updated modeling, an initial projected annual IVT template manufacturing capacity of approximately ten (10) grams with 100% cell-free workflow;

  • 10mg to gram-scale production in 6-14 weeks with multiple purification options;

  • Dedicated warehouse, process development, analytical testing, and quality control areas;

  • The capacity to deliver chemically modified LineaDNA IVT templates paired with the Company's proprietary RNA polymerase to mitigate double-stranded DNA (dsRNA) contaminants in commercial-scale mRNA production; and,

  • A projected revenue capacity ranging from $10 million to $30 million, depending on product mix (sales of IVT template or the paired-IVT template and Linea™ RNA polymerase for mRNA production[1].)

"Once operational, our GMP facility stands ready to support the development of next-generation genetic medicines with a cell-free, enzymatic approach to IVT template production that confers the advantages of simplicity, purity, speed, flexibility, and scalability in a fractional footprint relative to conventional plasmid-DNA (fermentation)-based IVT template manufacturing processes. We believe we are in an unmatched position to help bring the advantages of synthetic DNA to our clients to develop innovative therapies," stated Dr. James A. Hayward, chairman and CEO of Applied DNA.

Added Clay Shorrock, president of LineaRx, Inc., "We believe the upcoming operational launch of our GMP facility is a pivotal junction for the Company, representing the final piece of a multi-year business strategy to commercialize our LineaDNA and Linea IVT platforms and return us to a growth trajectory. With a strong GMP sales funnel for IVT templates and in active negotiations on our first supply agreement, we look forward to engaging with our therapeutic developer and CDMO customers to support their cell-free DNA needs."

[1] Based on internal Company data and modeling.

About the LineaDNA™ and Linea™ IVT Platforms

The LineaDNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the LineaDNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the LineaDNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs. The Linea IVT platform combines DNA IVT templates manufacturing via the LineaDNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the fact that there has never been clinical trial material and/or commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K on December 17, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]

Program contact: Clay Shorrock, 631-912-6454, [email protected]

Web: www.adnas.com

X: @APDN

###

SOURCE: Applied DNA Sciences, Inc.

J.P.Estrada--TFWP